The global insulin biosimilar market is on track for significant expansion, with an estimated valuation of approximately USD 3,008.0 million in 2024. Exhibiting a year-on-year growth rate of 7.2%, the market is expected to continue its upward trajectory, with overall sales of insulin biosimilars projected to rise at a compound annual growth rate (CAGR) of …